AMCS Acquires Qv21 Technologies, Strengthening Its Transportation Management Capabilities
4.9.2024 15:00:00 CEST | Business Wire | Press release
Qv21 Technologies’ fleet management and logistics SaaS solutions to support improved waste-to-resource conversion and sustainability for organizations
AMCS, a global leader of sustainability software for foundational industries, announced today its acquisition of Qv21 Technologies, a leading provider of fleet management and logistics SaaS solutions for short-haul, bulk commodity transportation, for an undisclosed amount.
Founded in 2009 in Austin, Texas, Qv21 Technologies enables short-haul and bulk commodity trucking companies of all sizes to increase operational visibility and improve overall efficiency. With their mission of enabling Logistics Without Barriers™, Qv21’s powerful solution, The LogisticsFramework™ (TLF), streamlines business processes from order to invoice. Backed with robust data management, workflow automation, and analytics capabilities, Qv21 ensures organizations are in complete control of their operations while boosting their savings and profit margins.
The innovative fleet management and logistics solutions by Qv21 Technologies, along with its North American footprint and focus on bulk material transportation, are highly complementary to the AMCS Platform, benefiting customers of both organizations. The acquisition empowers AMCS to expand the capabilities of the AMCS Platform, enabling resource-intensive industries to achieve their sustainability goals faster, more efficiently, and profitably.
“Qv21 Technologies has consistently offered innovative solutions built for short-haul, bulk commodity transportation companies, enhancing operational excellence for leading organizations, including those in the waste and recycling sectors,” said Jonathan Currie, CEO, Qv21 Technologies. “Qv21's commitment to 'Logistics Without Barriers' boosts efficiency and profitability for transporters. Beyond the opportunities for business expansion, our partnership with AMCS further strengthens this pursuit of operational excellence for our clients and accelerates our collective vision for greater sustainability.“
This acquisition paves the way for several synergistic opportunities to be realized, specifically aiding organizations in the long-haul transport of bulk commodities that can support a more circular economy vision. Materials that were previously considered waste and destined for landfill sites can now be effectively directed towards reuse or recycling facilities. With Qv21, AMCS can provide organizations with a solution for a more structured, efficient approach to resource utilization and improved waste management, translating to meaningful progress toward their sustainability goals.
“The strategic addition of Qv21 Technologies signifies a crucial advancement for AMCS, reinforcing our position at the forefront of Performance Sustainability,” explained, Jimmy Martin, co-founder and CEO, AMCS. “This partnership provides tremendous opportunities, specifically for companies engaged within bulk material transportation, to reach their sustainability goals faster. The features that Qv21 brings to the table serve to enhance our capabilities at AMCS, strengthening our ability to support our clients' drive towards enhanced resource management, greater efficiency, sustainability, growth, and profitability.”
AMCS’ Performance Sustainability Suite is the operating system for foundational industries that makes sustainability and profitability possible. The suite manages the running of day-to-day operations such as contracts and pricing, logistics and transportation, materials and resources, health and safety, and sustainability intelligence. The AMCS Performance Sustainability Suite drives growth and profitability, optimizes efficiency and safety, powers corporate sustainability initiatives, and prepares businesses for the circular economy and the future. With AMCS, businesses can improve performance and scale more easily, enabling foundational industry professionals to leave the planet in a better way than they found it.
About Qv21 Technologies
Founded in 2009, Qv21 Technologies is an industry-leading SaaS company specializing in Transportation Management Systems for short-haul, bulk commodity transport. Dedicated to building cloud-based tools, Qv21 supports transporters, carriers, and commodity buyers in navigating industry challenges.
Qv21 Technologies’ flagship solution, The LogisticsFramework™ (TLF), increases operational visibility and streamlines business processes, from order to invoice. As a committed technology provider to trucking companies of all sizes, Qv21 makes increasing savings and profit margins achievable, restoring control of operations back to the organization. Learn more at www.qv21.com
About AMCS
At AMCS we are focused on Performance Sustainability – enabling resource-intensive industries to boost sustainability and profitability. Built on decades of experience, our purpose-built software solutions are designed by people who understand your business, providing practical solutions for the resources, waste, recycling, transportation, manufacturing, and utilities industries.
Headquartered in Ireland, and with offices in Europe, the USA, and Australia, AMCS is a global market leader with over 1,300 mission-driven team members. The combined expertise of our team allows AMCS to deliver innovative solutions and extensive insight, helping customers to drive growth and achieve lasting success. As a trusted global partner, we work with 3800 customers in more than 80 countries delivering digital solutions that create meaningful and measurable impact by increasing customer satisfaction, enhancing sustainability, and boosting margins.
At AMCS, we're ready to innovate with you - deploying our experts, processes, and technology to drive your business forward and prepare you for success in a more sustainable, net zero carbon future. Learn more at: www.amcsgroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904279752/en/
Contacts
Media
Media
Dwayne Weppler
AMCS Group
dwayne.weppler@amcsgroup.com
226 581 5166
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom